Please Wait...

Classic Blog

You are here

Governance and Collaboration: CTMS Checklist

  • 0
  • Array
  • 02 Mar

A recent market research report forecasts that the eClinical solutions market will be worth 5.98 billion (USD) by 2020. With sponsors and CROs adopting new eClinical software, or replacing legacy systems, such as clinical trial management systems (CTMS), vendors are emerging with new software to stake a claim in this growing market.

Read More

The Scoop from SCOPE Summit 2016

  • 0
  • Array
  • 25 Feb

SCOPE Summit 2016 was a busy and exciting event for the Bioclinica team! In addition to the great discussions at the Bioclinica booth, Ron Burns, VP, Product Management, Bioclinica eHealth Solutions, held a session entitled, "Integrating Mobile Application Generated Patient Data into Your Risk-Based Monitoring Strategy." This session included Bioclinica eHealth App xChange Partner, AiCure.

Read More

Get a First-Hand Glimpse into the Power of Mobile Application Generated Patient Data at SCOPE Summit 2016

  • 0
  • Array
  • 18 Feb

The rapid growth of technology is revolutionizing the way clinical trials are conducted. Increasing adoption of smartphone use -- forecasted to reach over 6 billion by 2021 – combined with the growing biosensors market opens up new possibilities for a variety of healthcare-related uses. Innovative patient-centered mobile applications and biosensors now connect patients with physicians and other healthcare providers.

Read More

Prompt Site Payments Key to Site Engagement

  • 0
  • Array
  • 05 Feb

When it comes to achieving success in clinical trials, it truly takes a team. Sponsors, investigative sites and patients must work in partnership to complete this important work. However, with weighty matters in the clinical development process - shrinking pipelines, shortened patent life, patient population considerations, global safety standards, and the list goes on - the needs of investigative sites can be overshadowed.

Read More
CDISC

CDISC Public Courses in Audubon, March 2-12: Register with CDISC today!

  • 0
  • Array
  • 04 Feb

Here's a great opportunity to learn CDISC from CDISC at Public Courses being held in Audubon, Pennsylvania at Bioclinica's eHealth Headquarters on March 2-12. (Other dates and locations are available).

Why take CDISC Training?

Read More

Necessity and Associated Benefits of Having Post-Approval Specific Technology

  • 0
  • Array
  • 26 Jan

Importance of selecting technology specifically designed to address the needs of post-approval research

Over the last decade, across the globe, the regulatory landscape has changed considerably, with greater focus and awareness on pharmaceutical products post-approval. Legislation, coupled with public concerns about the safety of marketed drugs and the need to evaluate safety and effectiveness of the marketed products in a real-world setting is forcing many companies to embark on post-approval research.

Read More

Bioclinica Demonstrates EHR to CDASH (E2C) Standard

  • 0
  • Array
  • 06 Jan

Ever since the US FDA introduced Meaningful Use requirements calling for medical practices to begin using EHR systems, the race was on to find a way to pull the data from EHR systems into the EDC systems electronically.  Many options have been tried − most focused on accessing the data from the EHR in the native HL7 format.  While this solution works, it's not easy to do. One of the stumbling blocks is the inability of site personnel to access this type of data from their EHR.

Eager to find a solution, our Express EDC team rolled up its sleeves to work on the CDISC initiative.

Read More
2015 Asia Events

Expanding Opportunities for Drug Development in Asia

  • 0
  • Array
  • 06 Oct

Asian biopharmaceutical companies are developing more products for the global market

Over the last decade, R&D activities, pharmaceutical market size, and the number of clinical trials in Asia has grown tremendously.  As a result, Asian biopharmaceutical companies are developing more products for commercialization in the global market, and International drug development service companies have moved many R&D functions and commercial operations to the APAC region.

Read More
CSF biomarkers & Alzheimer's Disease

CSF Biomarkers and the advancement of Alzheimer's Disease Trials

  • 0
  • Array
  • 03 Aug

The Use of CSF Biomarkers in Alzheimer's Clinical Trials

The Importance of Early Diagnosis for AD Last month, scientists, clinicians, drug sponsors, and regulators gathered in our nation's capital at the annual Alzheimer's Association International Conference (AAIC) to share recent advances in AD research and clinical drug development.
Read More

How RBM Technology Strengthens Sponsor-Site Ties

  • 0
  • Array
  • 10 Jun

Creating A Healthier Sponsor-Site Dynamic

Why does it seem like problems surface at clinical research sites right about when the study team is either busy preparing for a monitoring visit or immediately following one?

Read More
Imaging biomarkers, molecular imaging in oncology clinical trials

Leveraging Imaging Biomarkers to Improve Drug Development

  • 0
  • Array
  • 02 Jun

Molecular Imaging – Valuable Drug Development Tools

Clinicians need ways to better predict patient responses

The estimated cost for developing a drug is approaching upwards of $5 Billion dollars with a process spanning well over a decade. Coupled with high failure rates in late phase clinical trials and increased complexities in acquiring and analyzing clinical trial data, traditional approaches based on the premise of "one size fits all" are becoming less cost effective and suboptimal.

Read More

eClinical Lessons Learned

  • 0
  • Array
  • 01 Jun

eClinical Insights Shared at the BioClinica Global User Conference

Part 2 of 2

In my last blog, I shared risk-based monitoring (RBM) lessons learned and RBM insights from the  BioClinica 5th Annual BioClinica Global User Conference held in May in Orlando, Florida.  Here is a recap of other eClinical sessions I had the pleasure of attending.

Read More

Pages

Trends in Asia Drug Development Market

  • 0
  • Array
  • 01 Nov

Innovation and Harmonization on the Rise

As R&D costs continue to hit new heights and domestic participation in clinical trials wane, more and more biopharmaceutical companies are seeking ways to mitigate costs and access new patient populations. Over the past decade, these driving market forces have contributed to a sharp rise in R&D activities, pharmaceutical market size, and the number of clinical trials conducted in Asia.

Read More

What Effect Does ICH E6 R2 Have on Risk-Based Monitoring and Overall Quality Risk Management?

  • 0
  • Array
  • 17 Oct

Last week I hosted a webinar called "What Effect Does ICH E6 R2 Have on Risk-Based Monitoring and Overall Quality Risk Management?" The webinar focused on the recent revision to the ICH Guideline for Good Clinical Practice (E6 R2), which primarily addresses quality management with a focus on risk identification, evaluation, control, review and reporting. During the session, I discussed:

Read More

2016 CDISC International Interchange: Standards, Metadata and the FDA

  • 0
  • Array
  • 13 Oct

The last week of September, I had the opportunity to be a chair on the EHR/MDR session at the 2016 CDISC International Interchange in Maryland. I always enjoy being involved with the CDISC Interchange; it is inspiring to see all the people who are passionate about submitting quality standardized data to the FDA to make better lives for us all.

Read More

Biomarkers for Alzheimer's Disease – Where are we now and Where are we going?

  • 0
  • Array
  • 04 Oct

Last July, the Alzheimer's disease community gathered in Toronto for the Alzheimer's Association International Conference (AAIC) to share the latest advances in AD research and clinical trials.

Dementia is a global health issue as it affects over 45 million people worldwide and is recognized as a public health priority by the World Health Organization (WHO). Alzheimer's disease (AD) is a fatal degenerative brain disease and is the most common cause of dementia, accounting for an estimated 60 to 80% of cases1.

Read More

Pages

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is divided into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging and Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Biomarker Laboratory. Our eHealth segment comprises an eClinical Solutions Division along with Safety and Regulatory Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

Our #Alzheimers expert's work will B showcased at #ADPD2017 Preview here https://t.co/nnbO9q8lVk @adpdnet
bioclinica (Yesterday)
#FunFriday ! A long time ago in a lab far far away.... https://t.co/2MrgKJhS07
bioclinica (Yesterday)
Smiles all around on Pizza Day today for @bioclinica eHealth in Audubon compliments of our CTO Andrew Masters. This… https://t.co/PbFoWnxn3B
bioclinica (2 days ago)
Missed Tuesday's webinar on agile #IRT? No worries! Catch it here > https://t.co/kKUIQEB0vI #Pharma #CRO #eClinical
bioclinica (2 days ago)
RT @ACROhealth: Where do you stand on regulating #mHealth & #Wearables in #clinicalresearch? w/ @bioclinica, @ICONplc, @INC_Research https:…
bioclinica (4 days ago)
RT @ACROhealth: ICYMI: @CCTAwareness’ Infographic on #clinicaltrials awareness for #Alzheimer’s and Parkinson’s treatments. https://t.co/84…
bioclinica (4 days ago)

Latest Blogs: